Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Posted: Sat Nov 07, 2020 2:57 pm
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Abstract
Background
Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy.
https://jitc.biomedcentral.com/articles ... 019-0793-8
With the advent of immunotherapies , I felt this to be an important article to share as our sarcoma lends itself highly to metastatic bone episodes as we find that the first site after primary is in the lungs.
Abstract
Background
Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy.
https://jitc.biomedcentral.com/articles ... 019-0793-8
With the advent of immunotherapies , I felt this to be an important article to share as our sarcoma lends itself highly to metastatic bone episodes as we find that the first site after primary is in the lungs.
Bone metastasis or "bone mets" occurs when cancer cells from the primary tumor relocate to the bone. Prostate, breast, and lung cancers are most likely to spread to the bone. However, other cancers are not excluded. Bone metastases do not begin from the bones but move there from the primary tumor site.